Belite Bio Q3 loss widens on higher costs
BLTE•Belite Bio’s third-quarter net loss widened year over year to $30.27 million as research and development and selling, general and administrative costs rose. Its lead drug, tinlarebant, received FDA priority review for Stargardt disease, with a decision expected by February 12, 2027.
1. Quarterly results
Belite Bio reported a third-quarter net loss of $30.27 million, with operating expenses of $36.91 million. Higher manufacturing expenses, consultant fees and sponsorship funding drove increased research and development costs, while higher professional service fees and team expansion raised selling, general and administrative costs.
2. Tinlarebant review
The FDA granted priority review to tinlarebant for Stargardt disease, with a decision expected by February 12, 2027. Belite Bio has submitted marketing applications in Japan, Singapore, the UK and Switzerland and is preparing for a commercial launch pending regulatory approval.
